Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 59 projects and 1 programmes
Accelerated development of vaccine benefit-risk collaboration in Europe
Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy
Applied public-private research enabling osteoarthritis clinical headway
Biomarkers for Enhanced Vaccine Immunosafety
Be The Cure
Cancer treatment and monitoring through identification of circulating tumour cells and tumour related nucleic acids in blood
Chemical manufacturing methods for the 21st century pharmaceutical industries
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
Collaboration on the optimisation of macromolecular pharmaceutical access to cellular targets
Drug Disease Model Resources
Diabetes research on patient stratification
Driving re-investment in R&D and responsible antibiotic use
European Bank for induced pluripotent Stem Cells
Electronic Health Records Systems for Clinical Research
European Lead Factory
European Medical Information Framework
European Medicines Research Training Network
European Gram-negative Antibacterial Engine
European prevention of Alzheimer’s dementia consortium
Integrating bioinformatics and chemoinformatics approaches for the development of Expert systems allowing the in silico prediction of toxicities
Delivering European Translational Information & Knowledge Management Services
European Autism Interventions - a Multicentre Study for Developing New Medications
European programme in Pharmacovigilance and Pharmacoepidemiology
European Patients' Academy on Therapeutic Innovation
Understanding chronic pain and improving its treatment
Standardization and development of assays for assessment of influenza vaccines correlates of protection
Incorporating real-life clinical data into drug development
Inhaled antibiotics in bronchiectasis and cystic fibrosis
Improving beta-cell function and identification of diagnostic biomarkers For treatment monitoring in diabetes
Intelligent Assessment of Pharmaceuticals in the Environment
Kinetics for Drug Discovery
Biomarkers and molecular tumour classification for non-genotoxic carcinogenesis
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury
New Drugs for Bad Bugs
Novel methods leading to new medications in depression and schizophrenia
Methods for systematic next generation oncology biomarker development
The Open Pharmacological Concepts Triple Store
Oral biopharmaceutics tools
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
Pharmaceutical Medicine Training Programme
Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases
New models for preclinical evaluation of drug efficacy in common solid tumours
Model-based preclinical development of anti-tuberculosis drug combinations
Physical Activity as a Crucial Patient Reported Outcome in COPD
Pharmacoepidemiological research on outcomes of therapeutics by a European consortium
Quantative imaging in cancer:connecting cellular process with therapy
Development of rapid point-of-care test platforms for infectious diseases
Safer and Faster Evidence-based Translation
European Modular Education and Training Programme in Safety Sciences for Medicines
Sarcopenia and physical frailty in older people: multi‐component treatment strategies
Stem cells for biological assays of novel drugs and predictive toxicology
Surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools
Molecular basis of the bacterial cell wall permeability
Unbiased biomarkers for the prediction of respiratory disease outcomes
Unrestricted leveraging of targets for research advancement and drug discovery
Recognising Adverse Drug Reactions
Zoonotic anticipation and preparedness initiative
